CAMBRIDGE, Mass., Apr. 11, 2022 /Business Wire/ — Vesigen Therapeutics, Inc., a biotechnology company pioneering a novel extracellular vesicle delivery technology, ARMMs, today announced the appointment of Paulash Mohsen as Chief Executive Officer.
“Paulash joins Vesigen with a broad range of skills, experience and accomplishments that are an excellent fit to lead an emerging innovation-focused biotechnology company such as Vesigen,” said Gerald Chan, Sc.D., Chairman of Vesigen’s Board of Directors. “His experience at both large pharma and small biotech companies will be invaluable as we continue advancing our novel programs. On behalf of our Board and management team, we welcome Paulash and look forward to his executive leadership.” Mr. Mohsen is a seasoned biopharmaceutical executive who has served in a variety of roles across multiple disciplines. Prior to his appointment at Vesigen, he served as Chief Business Officer at YumanityTherapeutics, and helped the company grow from a seed stage, research-based startup to a publiccompany, with a lead clinical program in Parkinson’s disease. He was responsible for securing a strategic research collaboration and license agreement with Merck & Co. for two pipeline programs in amyotrophic lateral sclerosis and frontotemporal lobar dementia. Before Yumanity, Mr. Mohsen served as Country Manager in Canada for Cubist Pharmaceuticals (acquired by Merck), where he led the company’s first international operation from conceptualization through commercialization. In this role, he oversaw the approval and launch of two novel anti-infective therapeutics and led the company’s commercial, scientific and administrative functions. Mr. Mohsen joined Cubist via acquisition of Optimer Pharmaceuticals, where he was Vice President, Strategy and Business Operations and helped establish the U.S. commercial infrastructure and led launch preparedness for DIFICID, an anti-infective. Preceding Optimer, Mr. Mohsen held strategic and operational roles at Pfizer, including Vice President of Strategy and Vice President, Multi-Channel Management. Mr. Mohsen holds a B.S. in Chemical Engineering from Brown University, an M.S. in Chemical Engineering from the Massachusetts Institute of Technology and an MBA from Harvard Business School.
Vesigen is a biotechnology company developing drugs based on its patented ARRDC1-mediated microvesicles (ARMMs) technology, a class of fusogenic extracellular vesicles produced by cells to package and deliver communication signals between cells and tissues. Currently, a wide range of therapeutic agents, including RNAs, proteins, and gene-editing complexes have been packaged into ARMMs and functionally delivered intracellularly in vitro and in vivo.
“What attracted me to Vesigen was both its innovative platform and the experience and ingenuity of its management team and research staff,” said Mr. Mohsen. “I am excited to begin working with this worldclass team to break through delivery barriers and enable the next generation of therapeutics for patients worldwide.”
About Vesigen Therapeutics
Vesigen Therapeutics is a biotechnology company advancing groundbreaking therapies directed to intracellular targets using a fusogenic extracellular vesicle delivery technology. Our patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), is expanding the universe of druggable targets by enabling the delivery of a wide range of payloads, including RNAs (mRNA, shRNA, ribozymes), proteins (signaling proteins, enzymes, antibody fragments), and gene-editing complexes (Cas9/gRNA) directly into the cytoplasm of target cells. The team is committed to leveraging ARMMs technology to develop transformative medicines and address currently unmet medical needs. For additional information visit www.vesigentx.com.
ARMMs vesicles (ARRDC1-mediated microvesicles) are a class of fusogenic extracellular vesicles produced by cells to package and deliver communication signals between cells and tissues. The ARMMs cellular machinery is partially hijacked by many enveloped viruses, such as HIV and Ebola, to produce viruses which bud out of host cells and have specific targeting properties. ARMMs possess unique properties not found in other classes of extracellular vesicles (e.g. exosomes), making them better suited for delivering therapeutic agents. It has been demonstrated that a wide range of labile and difficult to deliver therapeutic agents, including RNAs (mRNA, shRNA, ribozymes), proteins (signaling proteins, enzymes, antibody fragments), and gene-editing complexes (Cas9/gRNA) can be packaged into ARMMs and functionally delivered intracellularly in vitro and in vivo. ARMMS vesicles were discovered and engineered into a drug delivery system in the lab of Quan Lu, PhD, Professor of Environmental Genetics and Physiology at the Harvard T.H. Chan School of Public Health with support in particular from Harvard’s Blavatnik Biomedical Accelerator. Vesigen will advance the ARMMs platform to develop innovative medicines for patients through an exclusive license agreement with Harvard University.
Manager, Business Operations